NCT07667335
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Oct 15, 2026 to Oct 20, 2026
- Notable Eligibility criteria shortened, about 4 words
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 45 words
- Start date moved earlier from Dec 1, 2026 to Oct 15, 2026
- Secondary endpoints: details revised at 2 of 5 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients receive quemliclustat IV on day 1, enfortumab vedotin IV on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy during screening and optionally undergo throughout the study. Patients also undergo CT/MRI and blood sample collection throughout the study.
Drugs: Quemliclustat, Enfortumab Vedotin
Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure
Biologicals: Pembrolizumab
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States